CHMP2A Antibody

What is CHMP2A and what cellular functions does it perform?

CHMP2A, also known as Vps2-1, belongs to the chromatin-modifying protein/charged multivesicular body protein (CHMP) family. It functions as a core component of the ESCRT-III complex with diverse cellular roles:

• Multivesicular body (MVB) formation and sorting of endosomal cargo proteins

• Degradation of surface receptor proteins via the endolysosomal pathway

• Membrane fission events, including cytokinesis at the midbody of dividing cells

• Nuclear envelope sealing and mitotic spindle disassembly during late anaphase

• Viral budding, particularly in HIV-1 p6- and p9-dependent virus release

• Regulation of immune cell-mediated antitumor activity

CHMP2A localizes to distinct subcellular regions depending on cellular context: late endosome membranes, the midbody during cell division (in two distinct rings on either side of the Fleming body), and the reforming nuclear envelope on chromatin disks during late anaphase .

Why do I observe different molecular weights for CHMP2A in Western blots?

Although the calculated molecular weight of CHMP2A is 25.1 kDa, researchers frequently observe bands at 28-32 kDa in Western blot applications. This discrepancy arises from several factors:

This difference is attributed to:

• Post-translational modifications altering electrophoretic mobility

• Structural properties affecting migration in SDS-PAGE

• Some antibodies report observing bands at both 28 kDa and 31 kDa, potentially representing different isoforms or modified versions

When validating a new CHMP2A antibody, researchers should expect to observe bands in this range rather than precisely at the calculated molecular weight .

What applications are CHMP2A antibodies validated for?

CHMP2A antibodies are validated for multiple research applications with specific recommended dilutions:

For IHC applications, antigen retrieval with TE buffer pH 9.0 is recommended, though citrate buffer pH 6.0 can be used alternatively . The appropriate dilution should be determined empirically for each experimental system, as recommended by antibody manufacturers .

How should I validate a CHMP2A antibody for my research application?

A rigorous validation protocol for CHMP2A antibodies should include:

• Specificity assessment:

  • Western blot analysis showing bands at the expected molecular weight (28-32 kDa)

  • Testing in multiple cell lines (HepG2, HEK-293, HeLa cells have shown positive detection)

  • Knockout/knockdown experiments using CRISPR-Cas9 or siRNA approaches

• Cross-reactivity verification:

  • Testing against appropriate species samples if cross-reactivity is claimed

  • Many antibodies show reactivity with human, mouse, and rat samples

• Application-specific validation:

  • For IHC: Testing in relevant tissues with appropriate controls (human liver cancer tissue has shown positive results)

  • For IF: Confirming subcellular localization consistent with known CHMP2A distribution

  • For IP: Verifying precipitation of CHMP2A and its interaction partners, particularly CHMP3

• Citation review:

  • Reviewing published literature using the specific antibody for your application

  • Some antibodies have extensive citation records for specific applications (e.g., multiple published applications for WB, IF, and KD/KO experiments)

These validation steps ensure reliable and reproducible results in downstream experiments and are critical for data interpretation in CHMP2A research.

What are the best experimental approaches to study CHMP2A-CHMP3 interactions?

The CHMP2A-CHMP3 interaction is critical for ESCRT-III function. Based on structural and biochemical studies, several approaches are effective for investigating this interaction:

• Co-immunoprecipitation:

  • Use CHMP2A antibodies to pull down protein complexes and probe for CHMP3

  • The interaction involves extensive surface contact: 2026 Ų of CHMP2A and 1997 Ų of CHMP3 surfaces, with 55 and 51 interface residues respectively

• Disulfide crosslinking:

  • Introducing cysteine pairs at specific residues (e.g., CHMP2A_D57C with CHMP3_S75C or CHMP2A_N18C with CHMP3_V110C)

  • Results in disulfide-linked heterodimers upon polymerization into tube-like structures

  • Can be validated by SDS-PAGE and negative staining electron microscopy

• Mutagenesis studies:

  • Mutating interface residues prevents polymerization

  • Systematic mutation of specific residues can map critical interaction regions

• Structural visualization:

  • Cryo-electron microscopy has resolved CHMP2A-CHMP3 filaments at 3.3 and 3.6 Å resolution

  • These structures reveal heterodimer interactions and membrane association mechanisms

These approaches provide complementary information about the structural basis and functional significance of CHMP2A-CHMP3 interactions in various cellular contexts.

How can I design a CRISPR-Cas9 knockout system for CHMP2A functional studies?

The search results provide a detailed CRISPR-Cas9 protocol for CHMP2A knockout that can be adapted for various experimental systems:

• Guide RNA design and preparation:

  • Design guide RNAs targeting CHMP2A gene sequences

  • RNA oligos can be purchased from commercial sources (e.g., IDT) and resuspended in 1×TE buffer (pH 8) to 200 µM

  • Complex designed crRNAs with tracrRNA (e.g., Alt-R CRISPR-Cas9 tracrRNA ATTO 550)

• Cell nucleofection:

  • Use appropriate nucleofection systems (e.g., Amaxa 2D nucleofector)

  • Select appropriate kit for target cell type (e.g., Mouse Neural Stem Cell Nucleofector Kit)

  • Nucleofect approximately 8×10^5 cells following manufacturer's protocol

  • Seed cells in Matrigel-coated plates after nucleofection

• Single clone isolation and validation:

  • 48 hours post-nucleofection, plate cells in Matrigel-coated 96-well plates using limiting dilution

  • Collect single clones and assess CHMP2A deletion by:

    • PCR amplification and sequencing of the target region

    • Immunoblotting with validated CHMP2A antibodies

• Functional validation:

  • In vitro assays (e.g., NK cell-mediated killing for immune studies)

  • In vivo studies (e.g., orthotopic transplantation into appropriate animal models)

  • Compare phenotypes between wild-type and CHMP2A knockout cells/animals

This approach has been successfully employed to study CHMP2A's role in tumor immune evasion and can be adapted to investigate other CHMP2A functions.

How does CHMP2A contribute to membrane binding and remodeling?

CHMP2A exhibits specific structural features that enable membrane interaction and remodeling, as revealed by cryo-EM studies:

• Key membrane-interacting regions:

  • N-terminal region: Although CHMP2A residues 1-7 are disordered in structures, they are oriented by conserved prolines toward the lipid bilayer, with short amphipathic N-terminal helices likely inserting into the membrane

  • Basic residue clusters: The main membrane interaction surfaces locate to the elbow formed by helices 3 and 4 (residues K104 to R131), exposing six basic residues (K104, K108, R115, K118, K124, R131) that interact with negative membrane charges

• Electrostatic interactions:

  • The electrostatic potential map shows stretches of basic surfaces combined with negative and non-charged regions

  • Most of these basic residues are conserved in the yeast ortholog Vps2

• Complex binding mechanism:

  • Membrane binding is not solely electrostatic - alanine mutagenesis of some CHMP3 basic residues within the membrane interaction surface did not prevent CHMP2A-CHMP3 polymerization in vitro

  • These mutations also didn't affect the dominant negative effect of C-terminally truncated CHMP3 on viral particle release

• Polymer formation and membrane curvature:

  • CHMP2A-CHMP3 heterodimers assemble into filaments of different diameters

  • The polymerization mode positions specific protein regions at the membrane interface

  • This arrangement facilitates membrane deformation and remodeling necessary for processes like MVB formation, viral budding, and cytokinesis

Understanding these interactions is crucial for designing experiments to investigate membrane remodeling in various cellular contexts.

What is the role of CHMP2A in cancer immunology and potential therapeutic applications?

Recent research has uncovered CHMP2A as a significant regulator of antitumor immunity:

• Identification and mechanism:

  • CHMP2A was identified through a genome-wide CRISPR-Cas9 screen as mediating tumor resistance to NK cell activity

  • It regulates the secretion of tumor-derived extracellular vesicles (EVs) and chemokines

  • These EVs express NK cell activating ligands like MICA/B, acting as decoys to inhibit NK cell killing

  • EVs can also express TRAIL or FasL, inducing apoptosis in NK cells

  • The ESCRT complex repairs T cell-mediated perforin holes in tumor cells, preventing T cell-induced killing

• Experimental evidence from mouse models:

  • CHMP2A knockout in murine head and neck squamous carcinoma (4MOSC1) cells led to:

    • Enhanced NK-mediated tumor cell killing in vitro

    • Reduced tumor volume in vivo (in immunocompetent mice only)

    • Increased infiltration of CD4+ T cells, CD8+ T cells, and NK cells

    • Reduced myeloid-derived suppressor cells (MDSCs) in tumors

  • No growth difference was observed in immunodeficient mice, confirming the immune-dependent mechanism

• Therapeutic implications:

  • CHMP2A represents a novel targetable regulator of broad immune cell-mediated antitumor activity

  • Targeting CHMP2A and/or other ESCRT-III components provides a potential approach for cancer immunotherapy

  • Such therapies could block this immune-inhibitory mechanism and improve immune cell-mediated therapies

These findings highlight CHMP2A as a promising target for developing new cancer immunotherapeutic approaches and underscore the importance of further research into ESCRT-III function in immune regulation.

How do CHMP2A and CHMP2B differ functionally, and what experimental approaches can distinguish between them?

CHMP2A and CHMP2B are paralogs with overlapping but distinct functions in the ESCRT-III complex. Several experimental approaches can differentiate their specific roles:

• Viral budding studies:

  • HIV-1 budding assays reveal that CHMP3 synergizes with CHMP2A but not with CHMP2B to enhance budding efficiency

  • Truncated versions of CHMP3 exert dominant negative effects on HIV-1 budding

• Disease associations:

  • CHMP2B is established to be associated with frontotemporal dementia

  • CHMP2A is associated with breast adenocarcinoma and potentially with frontotemporal dementia and/or amyotrophic lateral sclerosis 7

• Differential experimental approaches:

  • Selective depletion: CRISPR-Cas9 knockout or siRNA knockdown of either paralog with rescue experiments

  • Structure-function analysis: Domain swapping between CHMP2A and CHMP2B to identify regions responsible for their unique functions

  • Interaction studies: Comparative analysis of binding partners using immunoprecipitation followed by mass spectrometry

  • Subcellular localization: Immunofluorescence with paralog-specific antibodies to identify distinct distribution patterns

• Process-specific assays:

  • While both contribute to ESCRT-III function, they may have differential importance in:

    • Multivesicular body formation

    • Viral budding mechanisms

    • Nuclear envelope reformation

    • Cytokinesis completion

    • Autophagosome closure

These approaches provide a framework for investigating the unique contributions of each paralog to cellular function and disease pathogenesis.

What are common pitfalls in CHMP2A antibody experiments and how can I avoid them?

When working with CHMP2A antibodies, researchers should be aware of several common challenges:

• Specificity concerns:

  • The observed molecular weight discrepancy (calculated 25.1 kDa vs. observed 28-32 kDa) may lead to misinterpretation

  • Solution: Validate antibody specificity using CHMP2A knockout or knockdown controls to confirm band identity

• Cross-reactivity issues:

  • While many antibodies claim reactivity with multiple species, actual performance may vary

  • Solution: Validate each antibody for your specific species of interest, even if cross-reactivity is claimed

• Application-specific optimization:

  • For IHC: Insufficient antigen retrieval can lead to false negatives

  • Solution: Test both recommended methods (TE buffer pH 9.0 and citrate buffer pH 6.0) to determine optimal conditions for your tissue samples

• Storage and handling:

  • Improper storage can reduce antibody performance

  • Solution: Follow manufacturer recommendations (typically -20°C storage with 50% glycerol); some antibodies specifically note "do not aliquot the antibody"

• Dilution optimization:

  • Using standard dilutions without optimization can yield suboptimal results

  • Solution: Titrate the antibody in each testing system to determine optimal dilution; recommended ranges are starting points only

• Inconsistent results across experiments:

  • Different lots may show variable performance

  • Solution: Maintain detailed records of antibody lot numbers and performance; consider testing multiple antibodies from different suppliers for critical experiments

By anticipating these challenges and implementing appropriate controls and optimization steps, researchers can generate more reliable and reproducible data with CHMP2A antibodies.

How should I interpret complex data when studying CHMP2A's role in multivesicular body formation?

CHMP2A's involvement in multivesicular body (MVB) formation presents several challenges for data interpretation:

• Redundancy considerations:

  • ESCRT-III components exhibit partial functional redundancy

  • When analyzing CHMP2A knockout/knockdown phenotypes, consider potential compensation by CHMP2B

  • Comparative studies with single and double knockouts can help distinguish unique vs. redundant functions

• Context-dependent effects:

  • CHMP2A function may vary across cell types and physiological states

  • Data interpretation should account for cell type-specific factors

  • The search results show different effects of CHMP2A knockout in different tumor cell lines (4MOSC1 vs. 4MOSC2)

• Temporal dynamics:

  • ESCRT-III assembly is transient and dynamic

  • Single-timepoint analyses may miss critical events

  • Live-cell imaging with temporal resolution is preferable to fixed-cell approaches when possible

• Structural interpretations:

  • CHMP2A-CHMP3 heterodimers form filaments of different diameters (resolved at 3.3 and 3.6 Å)

  • These structural variations likely reflect functional states or contexts

  • When interpreting structural data, consider how different assemblies might operate in distinct cellular processes

• Integration with other ESCRT complexes:

  • MVB formation requires sequential action of ESCRT-0, -I, -II, and -III

  • CHMP2A phenotypes may reflect disruptions at multiple points in this cascade

  • Comprehensive analysis should incorporate markers for each ESCRT complex

By considering these factors, researchers can develop more nuanced interpretations of experimental data and better understand CHMP2A's specific contributions to MVB formation in different biological contexts.

What are the latest research frontiers in CHMP2A biology requiring advanced antibody applications?

Several emerging areas in CHMP2A research present opportunities for innovative antibody applications:

• Cancer immunotherapy implications:

  • Recent work identifies CHMP2A as a regulator of immune cell-mediated antitumor activity

  • Advanced applications include multiplexed imaging of CHMP2A with immune cell markers in tumor microenvironments

  • Proximity labeling techniques combined with mass spectrometry can identify CHMP2A-associated proteins in immunological synapses

• Structural dynamics during membrane remodeling:

  • Super-resolution microscopy with specific CHMP2A antibodies can reveal assembly dynamics

  • Site-specific antibodies recognizing different CHMP2A conformations could distinguish active vs. inactive states

  • Correlative light and electron microscopy can connect CHMP2A localization with membrane ultrastructure

• Post-translational modification mapping:

  • The discrepancy between calculated and observed molecular weights suggests potential modifications

  • Modification-specific antibodies (phospho-specific, ubiquitin-specific) could reveal regulatory mechanisms

  • Temporal changes in modifications during cell cycle or stress responses represent unexplored territory

• Therapeutic targeting strategies:

  • Conformation-specific antibodies might selectively inhibit CHMP2A in pathological contexts

  • Intrabodies directed against CHMP2A could provide new research tools and potential therapeutic approaches

  • PROTAC-based approaches targeting CHMP2A in cancer cells could enhance immune-mediated killing

• Viral infection mechanisms:

  • CHMP2A's role in viral budding extends beyond HIV to other enveloped viruses

  • Advanced imaging of CHMP2A during viral infection cycles can reveal mechanistic details

  • Antibody-based inhibition of CHMP2A could present antiviral strategies

These frontier areas represent opportunities for researchers to apply existing CHMP2A antibodies in novel ways and develop new antibody tools to address specific questions in ESCRT biology and disease pathogenesis.

How might future CHMP2A antibody technologies advance our understanding of ESCRT-III biology?

Next-generation antibody technologies hold promise for revealing new aspects of CHMP2A biology:

• Single-domain antibodies and nanobodies:

  • Smaller size allows access to previously inaccessible epitopes

  • Superior penetration in tissue samples and potentially in live-cell applications

  • Can be used to detect specific CHMP2A conformations during ESCRT-III assembly and disassembly

• Bifunctional antibodies:

  • Combining CHMP2A binding with recruitment of specific effector proteins

  • Enabling targeted perturbation of CHMP2A function in specific subcellular locations

  • Creating synthetic proximity between CHMP2A and other proteins of interest

• Intracellular antibody fragments:

  • Expressed within cells to track and modulate CHMP2A in real-time

  • Can be coupled with optogenetic systems for spatiotemporal control

  • Allow for acute disruption of specific CHMP2A interactions without genetic modification

• Site-specific labeling strategies:

  • Enabling precise placement of fluorophores or other functional groups on CHMP2A antibodies

  • Improving FRET-based studies of CHMP2A interactions with other ESCRT components

  • Facilitating super-resolution imaging techniques to visualize ESCRT-III assemblies below the diffraction limit

These technological advances will complement existing genetic and biochemical approaches to provide a more comprehensive understanding of CHMP2A function in health and disease.

What are the emerging intersections between CHMP2A research and other fields of biology?

CHMP2A research is increasingly intersecting with multiple biological fields, creating opportunities for interdisciplinary studies:

• Cancer immunology:

  • CHMP2A functions as a regulator of both NK cell-mediated immunity and broader immune cell populations

  • Its deletion increases immune cell infiltration and reduces immunosuppressive cells in tumors

  • This positions CHMP2A at the intersection of cancer biology and immunology

• Neurodegenerative disease:

  • CHMP2A's association with frontotemporal dementia and/or amyotrophic lateral sclerosis connects ESCRT function with neurodegeneration

  • Understanding how ESCRT dysfunction contributes to protein aggregation and neuronal death represents an important research direction

• Developmental biology:

  • ESCRT-III components play critical roles in cytokinesis and membrane remodeling during development

  • Studying CHMP2A in developmental contexts may reveal tissue-specific functions

• Viral pathogenesis:

  • Beyond HIV, CHMP2A likely plays important roles in the life cycles of many enveloped viruses

  • Understanding these interactions could inform broad-spectrum antiviral approaches

• Synthetic biology:

  • CHMP2A's membrane-remodeling capabilities have potential applications in designing synthetic cells and organelles

  • Engineered CHMP2A variants could create custom membrane structures for biotechnology applications